Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HINT1 | P49773 | 4/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702978 | 1.00 | TYMP (0.68) | TYMPHPGDHINT1TAS1R3TAS1R1 | |
| SCHEMBL1738400 | 1.00 | TYMP (0.68) | TYMPHPGDHINT1TAS1R3TAS1R1 | |
| SCHEMBL21905181 | 0.94 | TYMP (0.67) | TYMPHPGDHINT1TAS1R3TAS1R1 | |
| SCHEMBL6420722 | 0.93 | TYMP (0.79) | TYMPHPGDHINT1GSK3ARPS6KA3 | |
| SCHEMBL17223100 | 0.92 | TYMP (0.64) | TYMPHPGDHINT1TAS1R3TAS1R1 | |
| SCHEMBL6460952 | 0.91 | TYMP (0.63) | TYMPHPGDHINT1TAS1R3TAS1R1 | |
| SCHEMBL313746 | 0.90 | TYMP (0.62) | TYMPHPGDHINT1TAS1R3TAS1R1 | |
| SCHEMBL313747 | 0.90 | TYMP (0.62) | TYMPHPGDHINT1TAS1R3TAS1R1 | |
| SCHEMBL5960204 | 0.90 | TYMP (0.69) | TYMPHPGDHINT1GSK3ARPS6KA3 | |
| SCHEMBL10433562 | 0.89 | TYMP (0.60) | TYMPHPGDHINT1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | TYMP 190/4885HPGD 3516/4885HINT1 1712/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | TYMP 190/4885HPGD 3516/4885HINT1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.